BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Exponent (EXPO) Reports Second Quarter 2007 Results


7/19/2007 9:30:30 AM

MENLO PARK, Calif., July 18 /PRNewswire-FirstCall/ -- Exponent, Inc. today reported financial results for the second quarter ended June 29, 2007.

For the second quarter of 2007, total revenues increased 22% to $50,637,000, as compared to $41,654,000 in the same period of 2006. Revenues before reimbursements increased 17% to $45,816,000, as compared to $39,053,000 in the same period of 2006. Net income increased 37% to $5,002,000, or $0.30 per diluted share, as compared to $3,650,000, or $0.21 per diluted share, in 2006.

EBITDAS(1) for the second quarter of 2007 increased 41% to $10,146,000, as compared to $7,204,000 in the same period of 2006. Exponent closed the second quarter of 2007 with $52.2 million in cash, cash equivalents and short-term investments. During the quarter, Exponent repurchased $8.8 million of common stock as part of its ongoing repurchase program.

"We are very pleased with our financial results for the second quarter, including strong revenue growth, improved utilization and expanding margins," commented Michael Gaulke, Chairman and CEO. "In the quarter several practices had very good performances, including electrical, thermal sciences, defense technology development, human factors, mechanics and materials, environmental, and ecological sciences.

"During the first half of 2007, we saw strong demand for our services and are pleased with our expansion in several strategic growth areas including health sciences consulting, product design consulting, energy consulting, and defense technology development. Exponent continues to work at maintaining its differentiated market position as a multidisciplinary engineering and scientific consulting firm with unparalleled technical expertise," concluded Mr. Gaulke.

For the first half of 2007, total revenues increased 19% to $99,510,000, as compared to $83,681,000 reported in the same period of 2006. Revenues before reimbursements increased 16% to $91,249,000, as compared to $78,672,000 in the same period of 2006. Net income for the first half of 2007 improved 35% to $10,057,000, or $0.61 per diluted share, as compared to $7,472,000, or $0.42 per diluted share, reported in the same period of 2006.

EBITDAS(1) for the first half of 2007 increased 38% to $20,900,000, as compared to $15,125,000 for the same period one year ago.

Today's Conference Call Information

Exponent will discuss its financial results in more detail on a conference call today, July 18, 2007, starting at 4:30 p.m. Eastern Daylight Time/ 1:30 p.m. Pacific Daylight Time. The audio on the conference call is available by dialing 800-240-2134. A live webcast of the call will be available on the Investor Relations section of the Company's web site at http://www.exponent.com/investors. For those unable to listen to the live webcast, a replay of the call will also be available on the Exponent web site, or by dialing 800-405-2236 and entering reservation #11093298.

About Exponent

Exponent is an engineering and scientific consulting firm providing solutions to complex problems. Exponent's multidisciplinary organization of scientists, physicians, engineers, and business consultants brings together more than 90 technical disciplines to address complicated issues facing industry and government today. The firm's consultants analyze failures and accidents to determine their causes and provide answers to help prevent such problems. In addition, Exponent evaluates human health and environmental concerns to find cost-effective solutions.

Exponent may be reached at (888) 656-EXPO, info@exponent.com, or http://www.exponent.com.

This news release contains, and incorporates by reference, certain "forward-looking" statements (as such term is defined in the Private Securities Litigation Reform Act of 1995, and the rules promulgated pursuant to the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended thereto under) that are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Such forward-looking statements are subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. When used in this document and in the documents incorporated herein by reference, the words "anticipate," "believe," "estimate," "expect" and similar expressions, as they relate to the Company or its management, identify such forward-looking statements. Such statements reflect the current views of the Company or its management with respect to future events and are subject to certain risks, uncertainties and assumptions. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, the Company's actual results, performance, or achievements could differ materially from those expressed in, or implied by, any such forward- looking statements. Factors that could cause or contribute to such material differences include the possibility that the demand for our services may decline as a result of changes in general and industry specific economic conditions, the timing of engagements for our services, the effects of competitive services and pricing, the absence of backlog related to our business, our ability to attract and retain key employees, the effect of tort reform and government regulation on our business, and liabilities resulting from claims made against us. Additional risks and uncertainties are discussed in our Annual Report on Form 10-K under the heading "Risk Factors" and elsewhere in the report. The inclusion of such forward-looking information should not be regarded as a representation by the Company or any other person that the future events, plans, or expectations contemplated by the Company will be achieved. The Company undertakes no obligation to release publicly any updates or revisions to any such forward-looking statements.

(1) EBITDAS is a non-GAAP financial measure defined by the Company as net income before income taxes, interest income, depreciation and amortization, and stock-based compensation. The Company regards EBITDAS as a useful measure of operating performance and cash flow to complement operating income, net income and other GAAP financial performance measures. Additionally, management believes that EBITDAS provides meaningful comparisons of past, present and future operating results. Generally, a non-GAAP financial measure is a numerical measure of a company's performance, financial position or cash flow that either excludes or includes amounts that are not normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP. This measure, however, should be considered in addition to, and not as a substitute or superior to, operating income, cash flows, or other measures of financial performance prepared in accordance with GAAP. A reconciliation of EBITDAS to GAAP is set forth below. EXPONENT, INC. CONDENSED CONSOLIDATED STATEMENTS OF INCOME For the Quarters Ended June 29, 2007 and June 30, 2006 (in thousands, except per share data) Quarter Ended Six Months Ended June 29, June 30, June 29, June 30, 2007 2006 2007 2006 Revenues Revenues before reimbursements $45,816 $39,053 $91,249 $78,672 Reimbursements 4,821 2,601 8,261 5,009 Revenues 50,637 41,654 99,510 83,681 Operating expenses Compensation and related expenses 30,207 26,044 60,229 52,790 Other operating expenses 5,305 4,967 10,442 9,732 Reimbursable expenses 4,821 2,601 8,261 5,009 General and administrative expenses 3,244 2,714 6,059 5,432 43,577 36,326 84,991 72,963 Operating income 7,060 5,328 14,519 10,718 Other income Interest income, net 460 533 944 1,031 Miscellaneous income, net 808 123 1,203 501 1,268 656 2,147 1,532 Income before income taxes 8,328 5,984 16,666 12,250 Income taxes 3,326 2,334 6,609 4,778 Net income $5,002 $3,650 $10,057 $7,472 Net income per share: Basic $0.33 $0.22 $0.67 $0.45 Diluted $0.30 $0.21 $0.61 $0.42 Shares used in per share computations: Basic 15,193 16,357 15,121 16,427 Diluted 16,532 17,631 16,461 17,711 EXPONENT, INC. CONDENSED CONSOLIDATED BALANCE SHEETS June 29, 2007 and December 29, 2006 (in thousands) June 29, December 29, 2007 2006 Assets Current assets: Cash and cash equivalents $6,243 $5,238 Short-term investments 45,958 52,844 Accounts receivable, net 61,492 48,208 Prepaid expenses and other assets 4,698 3,484 Deferred income taxes 3,821 2,232 Total current assets 122,212 112,006 Property, equipment and leasehold improvements, net 29,293 29,577 Goodwill 8,607 8,607 Other assets 10,565 11,026 $170,677 $161,216 Liabilities and Stockholders' Equity Current liabilities: Accounts payable and accrued liabilities $7,032 $4,887 Accrued payroll and employee benefits 23,667 21,773 Deferred revenues 4,200 4,066 Total current liabilities 34,899 30,726 Other liabilities 4,094 5,088 Deferred rent 1,987 1,097 Total liabilities 40,980 36,911 Stockholders' equity: Common stock 16 16 Additional paid-in capital 56,567 50,799 Accumulated other comprehensive income 125 93 Retained earnings 106,171 101,226 Treasury stock, at cost (33,182) (27,829) Total stockholders' equity 129,697 124,305 $170,677 $161,216 EXPONENT, INC. EBITDAS (1) For the Quarters Ended June 29, 2007 and June 30, 2006 (in thousands) Quarter Ended Six Months Ended June 29, June 30, June 29, June 30, 2007 2006 2007 2006 Net Income $5,002 $3,650 $10,057 $7,472 Add back (subtract): Income taxes 3,326 2,334 6,609 4,778 Interest income, net (460) (533) (944) (1,031) Depreciation and amortization 969 898 1,886 1,780 Stock-based compensation 1,309 855 3,292 2,126 EBITDAS (1) $10,146 $7,204 $20,900 $15,125 (1) EBITDAS is a non-GAAP financial measure defined by the Company as net income before income taxes, interest income, depreciation and amortization, and stock-based compensation. The Company regards EBITDAS as a useful measure of operating performance and cash flow to complement operating income, net income and other GAAP financial performance measures. Additionally, management believes that EBITDAS provides meaningful comparisons of past, present and future operating results. Generally, a non-GAAP financial measure is a numerical measure of a company's performance, financial position or cash flow that either excludes or includes amounts that are not normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP. This measure, however, should be considered in addition to, and not as a substitute or superior to, operating income, cash flows, or other measures of financial performance prepared in accordance with GAAP.

Exponent, Inc.

CONTACT: Brinlea Johnson, for Exponent, Inc., +1-415-489-2189,brinlea@blueshirtgroup.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES